Health Professional Radio - Podcast

Returning guest, Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, Inc., and former chairman of the global Biotechnology Innovation Organization (BIO) discusses the new COVID variant Delta-Plus, a virus that mutated from the highly infective Delta version, and why vaccinations are so crucial. #OvidTherapeutics #DeltaPlus #COVID Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is a former chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA). Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report.

Dr. Ryan Mathis, MD, Vice President of Commercial Strategy at PolarityTE discusses SkinTE™ an innovative alternative for the treatment of chronic wounds, like diabetic foot ulcers (DFUs). He talks about the science behind SkinTE™, how it's made of a patient’s own full-thickness skin, which retains the endogenous regenerative cellular populations found throughout his/her skin within multicellular segments. He also shares information from real-world studies of difficult to treat wounds. SkinTE™ is on track for IND submission in the second half of 2021. #woundcareskin #regenerativemedicine #tissueengineering Ryan K. Mathis, MD. Ryan earned his undergraduate and medical degrees at Penn State University before joining the Medstar Georgetown University Plastic Surgery Department as a resident. While at Georgetown, Ryan took leadership roles on the House Staff Quality Council and the Graduate Medical Education Council; he also received numerous awards from his peers and colleagues for distinguished clinical performa

Returning guest, Dr. Bruce Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai discusses new data presented at the 16th Congress of European Crohn's and Colitis Organisation (ECCO) from a trial evaluating biologic induction and maintenance therapy for moderately to severely active ulcerative colitis. #ECCO2021 #UlcerativeColitis Bruce E. Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai is the study spokesperson for the three-year data from the long-term extension (LTE) of UNIFI, a Phase 3 protocol designed to evaluate the safety and efficacy of STELARA induction and maintenance dosing for the treatment of moderately to severely active ulcerative colitis in ad

Leon Lerman, CEO of Cynerio, the leading provider of Healthcare IoT cybersecurity and asset management solutions discusses the biggest security challenges for healthcare in a post-COVID environment, why health systems should move to the Zero Trust model to secure their systems and devices, and whether governing bodies should provide cybersecurity requirements for healthcare. #Cynerio #HealthcareIoT Leon Lerman is the co-founder and CEO of Cynerio, Inc., a full-suite Healthcare IoT platform that enables healthcare providers to secure patient data and connected devices against cyber threats. He has over 15 years of experience in innovative technology development, served in Israel's elite Unit 8200 cyber technology division, has served as a trusted security advisor to Fortune 500 companies, and has earned international recognition for excellence in the cybersecurity industry.

Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus, a global leader in influenza prevention, discusses data from a first-of-its-kind co-administration study conducted by Novavax of the SARS-CoV-2 vaccine candidate (Novavax, NVX-CoV2373) and an approved influenza vaccine (Seqirus, Flucelvax Quadrivalent and Fluad).  He talks about the potential advantages for patients and physicians to co-administer an approved COVID-19 and influenza vaccine, how these findings may impact proposed immunization scheduling for varying age groups and alter CDC recommendations, and the importance of these findings as we approach a critical 2021/22 influenza season while many populations are still in need of a primary COVID-19 vaccine series or booster dose. #COVID #Influenza #Seqirus Dr. Gregg Sylvester serves as the Chief Medical Officer of Seqirus. He has been with the company since 2016, previously serving as Vice President of Medical Affairs. Prior to this, Dr. Sylvester held a variety of senior manage

Mike Lipps, CEO of Intelerad, a global leader in medical image management discusses why hospitals and health systems need fewer integrations to be able to truly manage their data and images and how a greater focus on data analytics can improve collaborative care. He also talks about the company's recent growth and momentum that furthers the company’s mission to provide customers with the most comprehensive enterprise imaging platform in the industry. #Interlad #Interoperability With over 20 years of software industry experience at companies such as Intuit and LexisNexis, Mike Lipps, CEO of Intelerad, has a proven track record of driving transformative growth. In his current role, Mike is focused on expanding Intelerad’s market penetration and coverage in the United States. Previously, as CEO of global enterprise software provider insightsoftware, Mike led the company through 14 acquisitions and over 400% growth in two years.

Dr. Rajesh Rajpal, MD, Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision discusses the launch and availability of their TECNIS Synergy™ in the United States and Canada. This next-generation presbyopia-correcting intraocular (PC-IOL) lens offers cataract patients the widest range of continuous vision, and best near vision among leading PC-IOLs, without the visual gaps seen with some multifocal technology. He talks about how this new next-gen lens was developed​,​ designed​,​ and the science behind it​, as well as other innovations in eye care solutions.​ #TECNISSynergy #Cataracts Rajesh Rajpal, M.D. is Chief Medical Officer and Global Head of Clinical and Medical Affairs for Johnson & Johnson Vision. In this role, Dr. Rajpal leads the integration of rapidly evolving medical and clinical insights into new product development to address unmet needs of patients and eye care professionals around the world. He also oversees clinical trials and the generation of surgical and vision care e

Dr. Clive Ward-Able is the Medical & Scientific Affairs Consultant of NeonMind Biosciences, a company exploring psilocybin as an alternative approach to weight loss and appetite suppression. He shares his insights on the potential of psychedelics in the treatment of obesity, the current trials underway, and what the future may hold. #NeonmindBiosciences #WeightLoss Dr. Clive Ward-Able is a physician and a pharmacist who has worked in the pharmaceutical industry for over 28 years with 21 of those at the executive level. He has worked in large and small pharmaceutical and biotechnology companies in Canada, the U.S., UK, Switzerland, and South Africa in the departments of R&D, medical, marketing, and sales. He is currently a member of the Board of Directors for Clinical Trials Ontario and has been a member of the Medical & Scientific Advisory Committee of Innovative Medicines Canada.

Dr. Karan Desai, MD, hand and upper extremity surgeon at Orlando Health Jewett Orthopedic Institute discusses how care for serious injuries at a level 1 trauma center can make the difference between amputation and recovery.  He recently saved the arm of a paramedic that was bitten by an alligator. #Injuries Karan Desai, MD, is a board-eligible hand surgeon with Orlando Health Jewett Orthopedic Institute, where he specializes in both operative and non-operative treatment of the hand and upper extremity. In addition to managing all aspects of traumatic and elective hand and upper extremity surgery, Dr. Desai also has extensive training in microsurgery and is skilled in complex reconstruction of the brachial plexus, peripheral nerves, bones, joints, and soft tissues, using methods such as free tissue transfers and nerve transfers. He earned his medical degree from the University of South Florida, School of Medicine in Tampa, where he graduated with Alpha Omega Alpha distinction and earned an undergraduate d

Dr. Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences discusses uterine fibroids and the recent FDA approval of MYFEMBREE® for the treatment of heavy menstrual bleeding associated with uterine fibroids.  MYFEMBREE is also being studied in endometriosis. #MyovantSciences #MYFEMBREE Juan Camilo Arjona Ferreira, MD, Chief Medical Officer of Myovant Sciences. Dr. Arjona Ferreira was previously Senior Vice President, Clinical Development at Shionogi. At Shionogi, Dr. Arjona Ferreira was responsible for leading the company’s U.S. Clinical Development organization and he served on the company’s U.S. Senior Leadership Team and the Global Scientific Committee. Prior to joining Shionogi, Dr. Arjona Ferreira spent over a decade at Merck & Co. where he was Executive Director of Clinical Research in Women’s Health. At Merck, he chaired the product development teams for all programs in contraception and women’s health. Dr. Arjona Ferreira earned his MD and completed his postgraduate specialist

Returning guest, Dr. Lucie Ide, MD, PhD, founder and CEO of Rimidi discusses why multiple point solutions in healthIT are only a temporary fix, how providers can integrate such solutions to achieve better health outcomes across their entire population of patients, and how combining remote patient monitoring (RPM), chronic care management (CCM), telehealth and patient reported outcomes (PROs) with clinical decision support solutions will further enable holistic care, and drive greater efficiency for staff. #Rimidi #ValueBasedCare Lucienne Marie Ide, M.D., PH.D., is the founder and CEO of Rimidi, a cloud- based software platform that enables personalized management of health conditions across populations. She brings her diverse experiences in medicine, science, venture capital and technology to bear in leading Rimidi’s strategy and vision. Motivated by the belief that we can do so much better as individuals, in industry and society, Lucie left clinical medicine to join the ranks of healthcare entrepreneurs who

As much of the world’s focus this past year has been on making progress in fighting off the COVID-19 pandemic, some remained focused on other raging epidemics that existed prior to the emergence of COVID-19 and continue to worsen over time.  For Rohan Palekar, CEO of 89bio, a clinical-stage biopharmaceutical start-up, the raging epidemic is non-alcoholic steatohepatitis (NASH) and he discusses how they haven't allowed the pandemic or the failures of other NASH treatments to hinder their progress of developing a solution for NASH.  He talks about what’s on the horizon for 89bio, including plans for continuing the development of their lead candidate, BIO89-100 with the initiation of a Phase 2b trial for the treatment of (NASH). #89bio #NASH Rohan Palekar is a seasoned C-suite executive with over 25 years of experience in the biopharmaceutical industry. Most recently, Rohan was the president and CEO of Avanir Pharmaceuticals (2015-2017) after serving as its EVP-Chief Operations Officer (2015). Rohan jo

Lead author, Dr. Philip Mease, MD, Director of Rheumatology Research at the Swedish Medical Center/Providence St. Joseph Health and Clinical Professor at the University of Washington School of Medicine, discusses new data from the Phase 3 DISCOVER-1 and DISCOVER-2 studies published in "The Lancet Rheumatology" (July 2021) on the efficacy of guselkumab on axial symptoms in patients with active psoriatic arthritis. Up to 70% of PsA patients experience axial symptoms. #TREMFYA #PsoriaticArthritis Philip J Mease, MD, is a Clinical Professor at the University of Washington School of Medicine and Director of Rheumatology Research at the Swedish Medical Center in Seattle, WA. Dr Mease’s clinical practice is based at Seattle Rheumatology Associates. He received his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as chief resident and fellow in rheumatology. Dr Mease c

Dr. Jennifer Gudeman, Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals discusses new clinical data from the pivotal phase 3 REST-ON clinical trial that was presented at the SLEEP 2021 Annual Meeting.  The investigational therapy, FT218, for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy is currently under review at the FDA with a PDUFA target date of October 15, 2021.  She also talks about the current treatment landscape and the unmet need among patients for a differentiated treatment option. #AvadelPharmaceuticals #SLEEP2021 Dr. Jennifer Gudeman was appointed Vice President, Medical and Clinical Affairs in December 2020. In 2017, Dr. Gudeman received the Healthcare Businesswomen’s “Rising Star” award. During her career, she has led or contributed to six commercial product launches and three clinical development programs, as well as led interactions with medical societies and patient advocacy organizations to help ensure that c

Dr. Jeffrey Cleland, Ph.D., Chairman, CEO and President of Ashvattha Therapeutics, a clinical stage biotech company discusses treatments that are in development to address inflammation of the brain caused by COVID.  They recently announced positive interim results on its ongoing phase 2 PRANA clinical study, which showed that OP-101, a novel hydroxyl dendrimer therapeutic, has the ability to successfully cross the blood brain barrier and suppress hyperinflammation.  The company is also developing a class of novel hydroxyl dendrimer therapeutics that they hope will become the future of targeted therapies and unlock new levels of patient care across oncology, ophthalmology, and inflammatory diseases. #AshvatthaTherapeutics Dr. Cleland has 30 years of industry experience in research and development, including more than a decade at Genentech, Inc. His experience in startups includes major roles in obtaining more than $450 million in capital at stages from Series A through D and exit via IPO including ov

Adam Levy, CEO of NEXGEL, advanced hydrogel solutions, discusses their unique water-based hydrogels designed differently from all other adhesives, tapes and surgical drapes that allow patients’ skin to remain hydrated, without rashes, and do not hurt patients when they are removed. #NEXGEL Adam Levy, CEO of NEXGEL has 34 years of expertise in capital markets, consumer products, marketing, television/radio advertising and direct to consumer sales. Previously, he led the successful turn-around of several financially distressed music companies as CEO of Warlock Record.

Millions of people worldwide are currently impacted by heart valve disease, and one in eight people aged 75 and older have the most common form, aortic stenosis (AS). Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery. Dr. Purvi Parwani, M.D., Director of the Women's Cardiovascular Health Clinic at Loma Linda International Heart Institute discusses new findings from a CardioSurve survey, sponsored by Medtronic and conducted by the American College of Cardiology, that reveals more than half of cardiologists believe patient preparation may lead to better quality discussions around treatment options for heart valve disease. However, the survey also uncovered cardiologists feel that their symptomatic severe AS patients are not as informed as they should be about their treatment options. Dr. Parwani will address why shared decision making is critical to individuali

Dr. Reid Robison, Chief Medical Officer of Novamind discusses psychedelic medicine and Novamind's leading network of psychedelic-assisted psychiatry clinics in America. Novamind is in a rapid expansion phase as they seek to build their growing network of clinics, research sites and therapeutic retreats specialized in psychedelic medicine. #Novamind #PsychadelicMedicine Dr. Reid Robison is a board-certified psychiatrist who was named Best Psychiatrist in Utah by Salt Lake City Weekly’s Best of Utah Body & Mind 2020. Dr. Robison is the co-founder of Cedar Psychiatry and serves as the Medical Director for the Center for Change, a leading Eating Disorder center. He is currently the coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders. As an early adopter and researcher of ketamine in psychiatry, Dr. Robison led a pivotal IV ketamine study for treatment-resistant depression by Janssen, leading up to the company’s recent FDA-approval of Spravato™. To date, Dr. R

Dr. Anthony Rullo, PhD, Assistant Professor of Medicine at McMaster University discusses the Anna Biosciences Syntem Platform that deploys engineered proprietary molecules to create synthetic immunity. Research suggests the platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. In partnership with McMaster University, Anna Biosciences has proven its initial successes in the laboratory and is now accelerating its commercialization effort to bring this potential COVID-19 treatment to market.  The platform also shows strong promise for use against cancer and other pathogens. #AnnaBiosciences #Syntem #COVID19 Anthony Rullo, Ph.D, is an Assistant Professor of Medicine at McMaster University where he has pioneered small molecule “proximity-inducing” therapeutic strategies with applications in immuno-oncology and anti-viral immunotherapeutics. In 2017 he founded the Rullo Laboratory, a translational chemical biology lab integrated within the department of medicine and the McMast

Dr. Brian LaMoreaux, MD, MS, Medical Director, Medical Affairs at Horizon Therapeutics plc discusses data presented at the 2021 European Alliance Of Associations For Rheumatology (EULAR) from the MIRROR open-label trial which looked at KRYSTEXXA® in combination with immunomodulator methotrexate in uncontrolled gout. EULAR abstract [AB0630]. Dr. Brian LaMoreaux is an internist and rheumatologist who joined Horizon Therapeutics in July 2016. He blends science and compassion in his approach to change outcomes for patients living with gout, recognizing that to change the understanding of gout, new research and continued education is required.Brian collaborates with the scientific community to push forward emerging data and to generate a foundation for new clinical studies so that clinicians may better address gout and ultimately improve outcomes for patients. Brian prioritizes having a personal impact on his community and provides one-on-one care as a volunteer clinician a free clinic in downtown Chicago. #Horizo